Literature DB >> 25318883

Carbohydrate antigens as potential biomarkers for the malignancy in patients with idiopathic deep venous thrombosis: a retrospective cohort study.

Miao Yu1, Yun-Hong Wang1, Ahmed M E Abdalla1, Wen-Qi Liu1, Fei Mei1, Jian Wang1, Chen-Xi Ouyang2, Yi-Qing Li3.   

Abstract

A variety of biomarkers have been identified in recent prospective and retrospective reports as being potentially predictive of venous thromboembolis (VTE), particularly idiopathic deep venous thrombosis (IDVT). This study identified a serum tumor biomarker for early screening of IDVT. A total of 128 IDVT patients (54 females and 74 males; average age: 50.9±17.4 years) were included. Carcinoembryonic antigen (CEA), ferritin, β2-microglobulin, cancer antigen (CA) 125, CA 15-3, CA 19-9, squamous cell carcinoma antigen (SCC), alpha-fetoprotein (AFP), prostate specific antigen (PSA), free PSA (f-PSA), and beta-human chorionic gonadotropin (β-HCG) in patients with IDVT were detected. Malignancies were histo- or cytopathologically confirmed. Of the 128 IDVT patients, 16 (12.5%) were found to have malignancies. Serum CEA, CA 125, CA 15-3, and CA 19-9 were found to be helpful for detecting malignancies in IDVT patients. Our study revealed a positive association between these markers and tumors in IDVT patients. On the other hand, SCC and AFP were not sensitive enough to be markers for detecting tumors in patients with IDVT. No significant differences were found in positive rates of ferritin and β2-microglobulin between tumor and non-tumor groups, and no significant difference exists in serum levels of ferritin and β2-microglobulin between the two groups. Carbohydrate antigens, CA 15-3 in particular, may be useful for differential diagnosis and prediction of malignancies in patients with IDVT.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25318883     DOI: 10.1007/s11596-014-1342-9

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  42 in total

1.  Beta2-microglobulin as a potential initiator of inflammatory responses.

Authors:  Jin Xie; Qing Yi
Journal:  Trends Immunol       Date:  2003-05       Impact factor: 16.687

Review 2.  Cancer and the prothrombotic state.

Authors:  Gregory Y H Lip; Bernard S P Chin; Andrew D Blann
Journal:  Lancet Oncol       Date:  2002-01       Impact factor: 41.316

3.  CA19-9 epitope a possible marker for MUC-1/Y protein.

Authors:  J Akagi; E Takai; Y Tamori; K Nakagawa; M Ogawa
Journal:  Int J Oncol       Date:  2001-05       Impact factor: 5.650

4.  International staging system for multiple myeloma.

Authors:  Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin
Journal:  J Clin Oncol       Date:  2005-04-04       Impact factor: 44.544

5.  Total loss of MHC class I is an independent indicator of good prognosis in breast cancer.

Authors:  Zahra Madjd; Ian Spendlove; Sarah E Pinder; Ian O Ellis; Lindy G Durrant
Journal:  Int J Cancer       Date:  2005-11-01       Impact factor: 7.396

6.  Soluble interleukin-2 receptors and other markers in primary lung cancer.

Authors:  N Poulakis; A Sarandakou; D Rizos; I Phocas; T Kontozoglou; D Polyzogopoulos
Journal:  Cancer       Date:  1991-09-01       Impact factor: 6.860

7.  Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy.

Authors:  A A Khorana; C W Francis; E Culakova; N M Kuderer; G H Lyman
Journal:  J Thromb Haemost       Date:  2007-03       Impact factor: 5.824

8.  Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature.

Authors:  David Shitrit; Boris Zingerman; Ariella Bar-Gil Shitrit; Dekel Shlomi; Mordechai R Kramer
Journal:  Oncologist       Date:  2005-08

9.  Free human chorionic gonadotropin beta subunit in gonadal and nongonadal neoplasms.

Authors:  I Marcillac; F Troalen; J M Bidart; P Ghillani; V Ribrag; B Escudier; B Malassagne; J P Droz; C Lhommé; P Rougier
Journal:  Cancer Res       Date:  1992-07-15       Impact factor: 12.701

10.  Idiopathic thromboembolism as the presenting sign of occult prostate cancer.

Authors:  M G Oefelein; M Brant; K Crotty
Journal:  Urology       Date:  1998-05       Impact factor: 2.649

View more
  3 in total

1.  Derivation and validation of a nomogram model for pulmonary thromboembolism in patients undergoing lung cancer surgery.

Authors:  Yuping Li; Lei Shen; Junrong Ding; Dong Xie; Jian Yang; Yanfeng Zhao; Angelo Carretta; René Horsleben Petersen; Sebastien Gilbert; Yasuhiro Hida; Servet Bölükbas; Hiran C Fernando; Gening Jiang; Yuming Zhu
Journal:  Transl Lung Cancer Res       Date:  2021-04

2.  Selected Tumour Biomarker Levels in Sheep with Pulmonary Adenomatosis.

Authors:  Cumali Özkan; Serkan Yıldırım; Zübeyir Huyut; Mustafa Özbek
Journal:  J Vet Res       Date:  2020-03-08       Impact factor: 1.744

3.  Epidemiology of Cancer-Associated Thrombosis in Asia: A Systematic Review.

Authors:  Lai Heng Lee; Chandramouli Nagarajan; Chuen Wen Tan; Heng Joo Ng
Journal:  Front Cardiovasc Med       Date:  2021-05-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.